Edition:
United States

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

2.01USD
3:59pm EST
Change (% chg)

$0.31 (+18.24%)
Prev Close
$1.70
Open
$1.73
Day's High
$2.27
Day's Low
$1.73
Volume
96,119
Avg. Vol
16,854
52-wk High
$3.75
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Azurrx Biopharma Initiates Phase II Clinical Trial Of MS1819-Sd For Cystic Fibrosis
Wednesday, 19 Dec 2018 08:01am EST 

Dec 19 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES INITIATION OF PHASE II OPTION CLINICAL TRIAL OF MS1819-SD IN CYSTIC FIBROSIS PATIENTS.AZURRX BIOPHARMA INC - PLANNED ENROLLMENT IS EXPECTED TO INCLUDE APPROXIMATELY 30 CF PATIENTS, WITH STUDY COMPLETION ANTICIPATED IN 2019.AZURRX BIOPHARMA INC - INITIAL TOP LINE DATA FROM PHASE II OPTION STUDY EXPECTED IN 2019.  Full Article

AzurRx Biopharma To Acquire Payment Rights To Lead Drug Candidate MS1819-SD From Protea Biosciences Group
Wednesday, 12 Dec 2018 08:00am EST 

Dec 12 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA TO ACQUIRE PAYMENT RIGHTS TO LEAD DRUG CANDIDATE MS1819-SD FROM PROTEA BIOSCIENCES GROUP.AZURRX BIOPHARMA INC - WILL PAY A TOTAL OF $1.55 MILLION FOR ASSETS.AZURRX BIOPHARMA INC - WILL ELIMINATE A $2 MILLION MILESTONE PAYMENT THAT WOULD HAVE BEEN DUE TO PROTEA UPON FDA APPROVAL OF MS1819-SD.AZURRX BIOPHARMA - TRANSACTION WAS APPROVED BY JUDGE PATRICK FLATLEY OF U.S. BANKRUPTCY COURT FOR NORTHERN DISTRICT OF WEST VIRGINIA.AZURRX BIOPHARMA - CO WILL NO LONGER BE OBLIGATED TO PAY 2.5% ROYALTY THAT WOULD HAVE BEEN DUE ON 1ST $100 MILLION OF NET SALES OF MS1819-SD.AZURRX BIOPHARMA - DEAL REMOVES REQUIREMENT PROTEA GET 10% OF TOTAL CONSIDERATION FOR MS1819-SD OR CO IF PRODUCT OR PROTEA WERE ACQUIRED BY 3RD PARTY.AZURRX BIOPHARMA - EXPECT TO ANNOUNCE ADDITIONAL KEY MILESTONES BEFORE YEAR-END FOR PHASE 2 STUDY OF MS1819-SD IN CYSTIC FIBROSIS PATIENTS.  Full Article

Azurrx Biopharma Files For Mixed Shelf Of Up To $50 Million - SEC Filing
Tuesday, 3 Jul 2018 05:26pm EDT 

July 3 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING.  Full Article

Laurence W Lytton Reports 6.15 Pct Passive Stake In Azurrx Biopharma As Of May 1
Friday, 11 May 2018 03:37pm EDT 

May 11 (Reuters) - AzurRx BioPharma Inc ::LAURENCE W LYTTON REPORTS 6.15 PERCENT PASSIVE STAKE IN AZURRX BIOPHARMA INC AS OF MAY 1 - SEC FILING.  Full Article

AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD
Thursday, 18 Jan 2018 08:00am EST 

Jan 18 (Reuters) - Azurrx Biopharma Inc ::AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY.AZURRX BIOPHARMA INC - IN PARTNERSHIP WITH MAYOLY SPINDLER, RECEIVED REQUIRED APPROVALS TO ADD A FRENCH SITE TO PHASE IIA STUDY OF MS1819-SD.  Full Article

AzurRx Biopharma files for mixed shelf offering of up to $10 mln
Wednesday, 1 Nov 2017 05:52pm EDT 

Nov 1 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​.  Full Article

Azurrx Biopharma, Mayoly Spindler announce IMPD submission
Friday, 20 Oct 2017 08:30am EDT 

Oct 20 (Reuters) - Azurrx Biopharma Inc ::Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission.Azurrx Biopharma - ‍IMPD submitted via European Medicines Agency clinical trial portal for approval prior to opening of clinical centers in France.  Full Article

AzurRx BioPharma files for stock shelf of upto $10 mln
Wednesday, 11 Oct 2017 06:08pm EDT 

Oct 11 (Reuters) - Azurrx Biopharma Inc :Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing‍​‍​.  Full Article